Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis

6 Sept 2024

Abstract excerpt

Abstract Background There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer’s disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF) Ng levels to distinguish between AD and frontotemporal lobar degeneration (FTLD) pathology and between different stages within the same disease, (b) the relationship...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyotrophic Lateral Sclerosis Research
Share to Dementia and Cognitive Impairment Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39242539
DOI: 10.1186/s13195-024-01566-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysisPMID 39242539Read ↗

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.Semantic proximity Read ↗

[Cerebrospinal fluid markers in early diagnosis of Alzheimer dementia].Semantic proximity Read ↗

Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.Semantic proximity Read ↗

Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine ApproachSemantic proximity Read ↗

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.Semantic proximity Read ↗

Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Semantic proximity Read ↗

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular eventsSemantic proximity Read ↗

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's diseaseSemantic proximity Read ↗

Emerging Biomarkers for Early Detection of Alzheimer’s Disease: A Systematic ReviewSemantic proximity Read ↗

Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an updateSemantic proximity Read ↗

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.Semantic proximity Read ↗

Performance of Plasma Amyloid β, Total Tau and Neurofilament Light Chain Levels for Alzheimer’s Disease IdentificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.